was taking was investigated by a review of the medical records. Table 1 Patient Demographics and Clinical Characteristics (N=106) Depression: Presence/absence of depression was assessed using the PHQ-9. 23 The PHQ-9 consists of 9
Search Results
Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
). Patient demographics and clinical characteristics are detailed in Table 1 . Of the patients, 98% were women, 78% were white, and 19.5% were black. Median age was 59.4 years (range, 50.7–67.7 years) at initiation of palbociclib treatment. Most patients (n
Rongbo Lin, Sunzhi Lin, Shuitu Feng, Qingyi Wu, Jianqian Fu, Fang Wang, Hui Li, Xiaofeng Li, Gaowang Zhang, Yongzhi Yao, Min Xin, Tianyang Lai, Xia Lv, Yigui Chen, Shangwang Yang, Yubiao Lin, Lixia Hong, Zhenyu Cai, Jianfeng Wang, Gen Lin, Shaowei Lin, Shen Zhao, Jinfeng Zhu, and Cheng Huang
pain control. Median initial dosages in opioid-tolerant patients were 1 mg (IQR, 0.5–2) and 1 mg (IQR, 0.5–2) in the PCA and non-PCA groups, respectively. Baseline characteristics ( Table 1 ) were well balanced between the 2 groups, with comparable ESAS
Antonious Hazim, Gordon Mills, Vinay Prasad, Alyson Haslam, and Emerson Y. Chen
involved CAR T-cell therapy. The most common cancer types were leukemia (16%), lung (12%), and breast (10%) ( Table 1 ). Table 1. Characteristics of Dose-Escalation Trials Of the 3,890 patients, 2,506 had both response and dose data, among whom the ORR (CR
Shehzad K. Niazi, Aaron Spaulding, Emily Brennan, Sarah K. Meier, Julia E. Crook, Lauren F. Cornell, Sikander Ailawadhi, Matthew M. Clark, and Teresa A. Rummans
Social Security Act) were invited to participate in the survey. The database contains information about hospital characteristics, services offered, and staffing, and responses are validated through review, comparison, and member checking by the AHA. 41
Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee
addition, we used the following ICD codes to identify patients with screening encounters: Z12.31, V76.11, and V76.12. Statistical Analysis We compared clinical and tumor characteristics between women diagnosed with cancer who received screening
Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung
,500 Commission on Cancer–accredited facilities. Jointly sponsored by the American College of Surgeons and American Cancer Society, it currently captures more than 70% of newly diagnosed cancers within the United States. Relevant patient characteristics, tumor
Lauren E. Kernochan and Rochelle L. Garcia
Edited by Kerrin G. Robinson
Carcinosarcoma of the uterus (malignant mixed Müllerian tumor [MMMT]) is an uncommon, typically extremely aggressive neoplasm histologically composed of malignant epithelial and mesenchymal (stromal) elements. Although the literature contains some debate, most authors now agree that most MMMTs derive from sarcomatous differentiation in a high-grade carcinoma. This article reviews the clinical and histopathologic features of this interesting neoplasm, with particular emphasis on recent data supporting MMMTs as primarily epithelial malignant neoplasms with areas of mesenchymal/spindle cell differentiation.
Thi Thanh Tam Bui, Quoc Thang Pham, Dang Anh Thu Phan, Quoc Dat Ngo, Thanh Hai Phan, Thi Ngoc Ha Hua, and Sao Trung Nguyen
Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz
data can provide further detail regarding the distribution of patient and renal cell carcinoma (RCC) characteristics within this special patient group. Based on these considerations, we reexamined patients with RCC with T1a 0- to 2-cm renal tumors to
